Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges, Tom Powles, Michael Staehler, Karim Bensalah, Rachel H. Giles, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Börje Ljungberg, Lorenzo Marconi, Axel S. Merseburger, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Axel Bex*

*Korrespondierende/r Autor/-in für diese Arbeit
63 Zitate (Scopus)

Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

OriginalspracheEnglisch
ZeitschriftEuropean Urology
Jahrgang76
Ausgabenummer2
Seiten (von - bis)151-156
Seitenumfang6
ISSN0302-2838
DOIs
PublikationsstatusVeröffentlicht - 08.2019

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)

Coronavirus-Bezug

  • Forschung zu SARS-CoV-2 / COVID-19

Fingerprint

Untersuchen Sie die Forschungsthemen von „Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren